drugset / Trial / NCT02163824
Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The primary purpose of this study is to determine the efficacy and safety of KPI-121 ophthalmic suspension compared to placebo in subjects who have undergone cataract surgery. The efficacy and safety of two different concentrations and two different dosing regimens of KPI-121 are also being assessed.
Timeline
- Start
- 2014-05
- Primary completion
- 2014-12
- Completion
- 2014-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Loteprednol Etabonate | Other / unclassified | 0.25 % | Topical |
| Comparator | Loteprednol Etabonate | Other / unclassified | 1 % | Topical |
Indications
No indication recorded.